It also suggests that the current routine testing of EGFR, ALK, and ROS1 performed on tumor tissue or plasma samples for selecting NSCLC patients treatable with first-line targeted therapy is actually not enough to predict the response to the approved TKIs. The gene discussed is ALK; the disease is neoplasm.